How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?
Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?
Crainiospinal irradiation (CSI) is extremely toxic...